Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:EDTNASDAQ:EYPTCVE:IMRNASDAQ:ITMR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDTSpectral MedicalC$0.81C$0.83C$0.46▼C$0.89C$227.81M0.9661,477 shs46,052 shsEYPTEyepoint Pharmaceuticals$9.66+1.2%$7.53$3.91▼$13.99$657.15M1.67815,809 shs769,489 shsIMRiMetal ResourcesC$0.15C$0.15C$0.13▼C$0.33C$813K1.5938,095 shs12,000 shsITMRItamar Medical$30.87$30.75$16.36▼$30.91$497.25M0.7390,796 shsN/AReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDTSpectral Medical0.00%0.00%-3.57%+5.19%+72.34%EYPTEyepoint Pharmaceuticals+1.49%+4.03%+32.45%+77.84%+14.92%IMRiMetal Resources0.00%-9.38%+11.54%-36.96%-51.67%ITMRItamar Medical0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDTSpectral MedicalN/AN/AN/AN/AN/AN/AN/AN/AEYPTEyepoint Pharmaceuticals2.4274 of 5 stars3.53.00.00.02.61.70.0IMRiMetal ResourcesN/AN/AN/AN/AN/AN/AN/AN/AITMRItamar MedicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDTSpectral Medical 0.00N/AN/AN/AEYPTEyepoint Pharmaceuticals 3.00Buy$25.67165.70% UpsideIMRiMetal Resources 0.00N/AN/AN/AITMRItamar Medical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ITMR, IMR, EYPT, and EDT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025EYPTEyepoint PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$28.005/29/2025EYPTEyepoint PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.005/16/2025EYPTEyepoint PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$30.00 ➝ $26.005/8/2025EYPTEyepoint PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$33.00 ➝ $27.00(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDTSpectral MedicalC$1.90M119.90C$0.01 per share82.50C($0.08) per share-10.13EYPTEyepoint Pharmaceuticals$43.27M15.36N/AN/A$4.93 per share1.96IMRiMetal ResourcesN/AN/AC$0.04 per share3.51C$0.91 per shareN/AITMRItamar Medical$41.03M12.12N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDTSpectral Medical-C$18.68M-C$0.07N/A∞N/AN/A-973.97%-93.22%N/AEYPTEyepoint Pharmaceuticals-$130.87M-$2.41N/AN/AN/A-261.91%-54.27%-41.75%8/6/2025 (Estimated)IMRiMetal Resources-C$2.26M-C$0.43N/A∞N/AN/A-37.31%-20.97%N/AITMRItamar MedicalN/A-$1.35N/AN/AN/AN/AN/AN/AN/ALatest ITMR, IMR, EYPT, and EDT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025EYPTEyepoint Pharmaceuticals-$0.65-$0.65N/A-$0.65$8.84 million$24.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDTSpectral MedicalN/A1.45%N/AN/AN/AEYPTEyepoint PharmaceuticalsN/AN/AN/AN/AN/AIMRiMetal ResourcesN/A3.01%N/AN/AN/AITMRItamar MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDTSpectral Medical26.030.610.45EYPTEyepoint PharmaceuticalsN/A7.857.79IMRiMetal Resources0.150.137.79ITMRItamar MedicalN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDTSpectral Medical12.99%EYPTEyepoint Pharmaceuticals99.41%IMRiMetal ResourcesN/AITMRItamar Medical42.19%Insider OwnershipCompanyInsider OwnershipEDTSpectral Medical18.18%EYPTEyepoint Pharmaceuticals4.46%IMRiMetal Resources2.57%ITMRItamar MedicalN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDTSpectral Medical29281.25 millionN/ANot OptionableEYPTEyepoint Pharmaceuticals12068.81 million65.74 millionOptionableIMRiMetal Resources1405.61 millionN/ANot OptionableITMRItamar Medical25716.11 millionN/ANot OptionableITMR, IMR, EYPT, and EDT HeadlinesRecent News About These CompaniesItamar Friedman, CEO & Co-Founder of CodiumAI – Interview SeriesMay 11, 2024 | unite.aiUItamar Ben-Gvir Injured in Car Accident – Developing StoryApril 27, 2024 | palestinechronicle.comPNational Security Minister Itamar Ben Gvir's daughter out of hospital following accidentApril 27, 2024 | msn.comsleep apnoeaApril 26, 2024 | pharmaphorum.comPITMR Historical DataOctober 17, 2023 | investing.comRead Your Way Around the WorldAugust 3, 2023 | nytimes.comCPAP versus Oxygen in Obstructive Sleep ApneaMay 19, 2023 | nejm.orgNFind the Best Medical SchoolsMay 14, 2023 | usnews.comItamar Ben-Gvir: 'Last year I saw suffering in Meron'April 29, 2023 | israelnationalnews.comIPolice chief said to order senior cops to avoid direct contact with Itamar Ben GvirMarch 15, 2023 | timesofisrael.comT'You ruined the police,' Tel Aviv district commander tells Israel Police chiefMarch 12, 2023 | jpost.comJBritish Foreign Secretary: We have no plans to engage with Ben GvirFebruary 26, 2023 | israelnationalnews.comIBen Gvir: This isn't what we signed up forFebruary 17, 2023 | israelnationalnews.comIBen-Gvir proposes ‘Defensive Shield 2’ operation as security cabinet to meetFebruary 13, 2023 | jpost.comJ'Heil Kahane': Meretz ex-chief under fire for tweet on Ben-GvirJanuary 27, 2023 | israelnationalnews.comIMansour Abbas: Ben Gvir thinks he is a superman who can solve all the problemsJanuary 17, 2023 | israelnationalnews.comIPolice spokesman: 'Ben-Gvir's appointment has deterrent effect on Arab sector'January 15, 2023 | israelnationalnews.comIYoung Settlement Forum to Ministers: "Now it's up to you"January 12, 2023 | israelnationalnews.comIItamar Ben-Gvir bans the Palestinian flagJanuary 11, 2023 | albawaba.comA'More than Itamar Ben-Gvir, it is the right-wing drift of public opinion in Israel that is worrying'January 11, 2023 | lemonde.frLNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeBreakout Momentum Plays You May Not Know AboutBy Nathan Reiff | June 6, 2025View Breakout Momentum Plays You May Not Know AboutITMR, IMR, EYPT, and EDT Company DescriptionsSpectral Medical TSE:EDTC$0.81 0.00 (0.00%) As of 03:53 PM EasternSpectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. The segments of the group are Spectral Medical Inc, which is the key revenue-generating segment that manufactures and sells its EAA diagnostic and certain proprietary reagents; Dialco Medical Inc segment; and Corporate.Eyepoint Pharmaceuticals NASDAQ:EYPT$9.66 +0.11 (+1.15%) Closing price 04:00 PM EasternExtended Trading$9.80 +0.15 (+1.50%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.iMetal Resources CVE:IMRC$0.14 0.00 (0.00%) As of 03:47 PM EasterniMetal Resources Inc., a junior exploration company, focuses on the acquisition, exploration, development, and evaluation of resource properties in Ontario and Quebec in Canada. The company explores for precious and base metal resources. Its flagship property is the Gowganda West project covering an area of approximately 147 squares kilometers located in Ontario; Kerrs Gold property covering an area of 665 hectares located in Ontario; and Ghost Mountain property consists of eleven claim units covering an area of 220 hectares located in Ontario. The company also holds 100% interest in the Carheil project encompasses approximately 5,400 acres of contiguous land located in the Abitibi region of Quebec. The company was formerly known as Adroit Resources Inc. and changed its name to iMetal Resources Inc. in November 2015. iMetal Resources Inc. was incorporated in 1993 and is headquartered in Vancouver, Canada.Itamar Medical NASDAQ:ITMRItamar Medical Ltd. engages in the research, development, marketing, selling, and leasing of non-invasive medical devices based on peripheral arterial tone signals. It develops and markets two products, namely, WatchPAT and EndoPAT. The WatchPAT diagnoses sleep apnea, which has been proven to be a substantial risk factor in cardiac disease. The EndoPAT diagnoses endothelial malfunction, which is a proven predictor of cardiovascular disease. The company was founded by Yaron Giora , Martin Gerstel, Peretz Lavie, and Daniel Gur on January 15, 1997 and is headquartered in Caesarea, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Jefferies Raises Broadcom Price Target to $315: 19% Upside Ahead Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock 3 Utility Stocks That Combine Income and Stability 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
